

## **ASH Meeting 2024 Participation**

**Friday, December 6; 9:00 AM-12:00 PM**  
**Training Program Directors Workshop**

[\*Innovative Fellowship Curriculum\*](#)

**Location:** Indigo 204 (Hilton San Diego Bayfront)

**Speaker:** Layla Van Doren

**Friday, December 6, 2024: 1:30 -2:00 PM**

**ASH-a-Palooza Program: Trainee Activities and Services**

[\*Blood Drop: Wellness\*](#)

**Location:** Station 4 (Gaslamp Quarter)

**Speaker:** Alfred Lee

**Friday, December 6; 1:30 PM-3:50 PM**

**ASH-a-Palooza Program**

[\*Blood Buddies: International Medical Graduates\*](#)

**Location:** Caf  Sevilla Restaurant (Gaslamp Quarter)

**Panelists:** Jessica M. Stempel

**Friday, December 6; 2:44 PM-3:25 PM**

**Symposia: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies Program: Scientific Workshops**

[\*Exploiting Epitranscriptomic Vulnerabilities: M6a and Splicing Factor Mutations in Myelodysplastic Syndrome \(MDS\)/Leukemia\*](#)

**Location:** Room 33 (San Diego Convention Center)

**Speaker:** Stephanie Halene

**Saturday, December 7; 10:00 AM**

**Session: 603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL**

[\*45: Cell Growth Trajectories of B-Cell Lymphomas Are Defined By Oscillations between MYC- and BCL6-Dependent States\*](#)

**Location:** Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

**Authors:** Zhangliang Cheng, Kohei Kume, Markus Muschen

**Saturday, December 7; 10:45 AM**

**Session: 603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL**

[\*48: Mechanism of Hyperactive PLC <sup>3</sup>1 Signaling in T-Cell Leukemia/Lymphoma\*](#)

**Location:** Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

**Authors:** Longhui Zeng, Xinyan Zhang, Yiwei Xiong, Nicole Hajicek, Xiaolei Su

**Saturday, December 7; 10:45 AM**

**Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire**  
[18: Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations](#)

**Location:** Room 24 (San Diego Convention Center)

**Author:** Justine Ryu

**Saturday, December 7; 11:15 AM-12:15 PM**

**Career Development Lunch**

[Adult Classical Hematology](#)

**Location:** Coronado Ballroom (Manchester Grand Hyatt San Diego)

**Presenter:** Alfred Lee

**Saturday, December 7; 12:00 PM**

**Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care**

[157: Preventing Long-Term Neurologic Disability in Hemophilia \(A\): Cost-Effectiveness of Efficizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia \(A\)](#)

**Location:** Room 31 (San Diego Convention Center)

**Authors:** Samira Glaeser-Khan, Rhys Richmond, Satoko Ito, MD, Robert D Bona, Harlan M. Krumholz, George Goshua

**Saturday, December 7; 1:15 PM**

**Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care**

[162: Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts \(ANC\)](#)

**Location:** Room 31 (San Diego Convention Center)

**Authors:** Satoko Ito and George Goshua

**Saturday, December 7; 2:00 PM**

**Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!**

[277: Sex, Lies, and Iron Deficiency in 2024: Cost-Effectiveness of Screening Ferritin Thresholds for the Treatment of Iron Deficiency in Women of Reproductive AgeClinically Relevant Abstract](#)

**Location:** Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

**Authors:** Daniel Wang, Samira Glaeser-Khan, Daniel Y Wang, Karthik Chetlapalli, Satoko Ito, George Goshua

**Saturday, December 7; 3:00 PM**

**Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!**

[281: Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding](#)

**Location:** Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

**Authors:** Daniel Y Wang, Samira Glaeser-Khan, Karthik Chetlapalli, Satoko Ito, George Goshua

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I**

[1075: Cytoplasmic Intron Retention As a Regulatory Mechanism of Mitochondrial Homeostasis in Erythroid Cells](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Rahul Roy, Prajwal Boddu, Manoj Pillai

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I**

[1228: Phenotypic and Transcriptomic Profiling of MPN Endothelium](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Lourdes M Mendez Anish V Sharda

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I**

[1480: Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I**

[1489: Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Wei Cheng, Rory M. Shallis

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 621. Lymphomas: Translational “ Molecular and Genetic: Poster I**

[1585: Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Archibald Enniful, Francine M. Foss, Rong Fan, Mina Xu

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster I**

[1812: Tet2 Loss in Hematopoietic Stem Cells Triggers Chromatin Reorganization through DNA Methylation Shifts](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Rahul Roy, Manoj Pillai, Prajwal Boddu

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster I**

[1815: MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Amro Baassiri, Jamie Maziarz, Holly Nicole Blackburn, Hannah Maul-Newby, Jennifer VanOudenhove, Martin Matthews, Sambuddha Paul, Wei Liu, Esen Sefik, Richard Flavell, Stephanie Halene

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster I**

[1813: SF3B1 Mutations Lead to Changes in Fine-Scale Chromatin Organization through Impaired Transcription](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Rahul Roy, Abhishek Gupta, Manoj Pillai, MD, Prajwal Boddu

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 655. Multiple Myeloma: Cellular Therapies: Poster I**

[2002: Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucl \(Cilta-cel\) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Noffar Bar, Iris Isufi

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I**

[2249: Screening for Cognitive Impairment and Depression in Sickle Cell Disease: How Are We Doing?](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jennifer A. Afranie-Sakyi, Modupe Karimi, Janis Bozzo, Joanna Cole, Layla N Van Doren, Cecelia Calhoun

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 904. Outcomes Research: Hemoglobinopathies: Poster I**

[2302: Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Priyanshi Maurya, Jingchen Liang, Daniel Prior, Sai Prasad Ramachandran, Yanhong Deng, Lakshmanan Krishnamurti

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 904. Outcomes Research: Hemoglobinopathies: Poster I**

[2304: Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Sai Prasad Ramachandran, Jingchen Liang, Daniel Prior, Priyanshi Maurya, Yanhong Deng, Lakshmanan Krishnamurti

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I**

[2319: Use of Calcineurin Inhibitor \(CNI\) and Eltrombopag \(EPAG\) Among Patients with Acquired Aplastic Anemia \(AA\) in the United States: Results from a Large National Database](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jessica M. Stempel, Rong Wang, Alfred I Lee, Xiaomei Ma, Nikolai A. Podoltsev

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 909. Education, Communication, and Workforce: Poster I**

[2442: Buprenorphine Knowledge and Attitudes Among Sickle Cell Disease Providers](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jennifer A. Afranie-Sakyi, Layla N Van Doren, Kimberly S. Vasquez, Cecelia Calhoun

**Saturday, December 7; 5:30 PM-7:30 PM**

**Session: 909. Education, Communication, and Workforce: Poster I**

[2445: Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Nikolai A. Podoltsev

**Saturday, December 7; 6:00 PM-9:00 PM**

[Hematology Inclusion Pathway \(HIP\) Oral Presentations - Classical Hematology](#)

**Location:** Marina Ballroom E (Marriott Marquis San Diego Marina)

**Moderator:** Cece Calhoun

**Sunday, December 8; 7:30 AM-9:30 AM**

**Medical Educators Symposium**

[General Session 3: Incorporating Health Equity Education in UME/GME Curriculum](#)

**Location:** Marina Ballroom FG (Marriott Marquis San Diego Marina)

**Presenter:** Layla Van Doren

**Sunday, December 8; 9:30 AM-11:00 AM**

**Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes**

[447: Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases \(COMMAND\)](#)

**Location:** Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

**Author/Moderator:** Rory Shallis

**Sunday, December 8; 9:30 AM-11:00 AM**

[Leveraging Quality Metrics to Maintain Support of Your Sickle Cell Disease Center](#)

**Location:** Room 33 (San Diego Convention Center)

**Presenter:** Cece Calhoun

**Sunday, December 8, 2024: 9:30 AM-11:00 AM**

**Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Program**

[615: Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes](#)

**Location:** Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

**Moderator:** Rory M. Shallis

**Sunday, December 8; 9:30 AM-11:00 AM**

**Sickle Cell Disease Centers Session**

**Location:** Room 33 (San Diego Convention Center)

**Co-chair:** Cece Calhoun

**Sunday, December 8; 9:45 AM**

**Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism, Differentiation and Inflammation**

**434: Linker Histone Regulates the Myeloid Versus Lymphoid Bifurcation of Multipotent Hematopoietic Stem and Progenitors**

**Location:** Room 7 (San Diego Convention Center)

**Authors:** Shangqin Guo, Kutay Karatepe, Bruna Mafra De Faria, Jian Zhang, Xinyue Chen, Anna Eastman

**Sunday, December 8; 11:00 AM-12:30 PM**

**LGBTQIA+ Community Networking Brunch (for in-person participants)**

**Location:** Coronado DE (Manchester Grand Hyatt San Diego)

**Panelists:** Diane Krause and Cristian Taborda

**Sunday, December 8; 11:30 AM-12:30 PM**

**Health Equity Rounds Lunch**

**Hematologic Aspects of Gender Affirming Care**

**Location:** Coronado Ballroom AB (Manchester Grand Hyatt San Diego)

**Speaker:** Ash Alpert

**Sunday, December 8; 12:00 PM**

**Session: 900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient-Centric Care**

**601: Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease**

**Location:** Room 25 (San Diego Convention Center)

**Authors:** Karthik Chetlapalli, Ayesha Butt, Satoko Ito, Daniel Wang, Cecelia Calhoun, Lakshmanan Krishnamurti, George Goshua

**Sunday, December 8; 4:45 PM**

**Session: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL**

**632: PKC $\delta$ -Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia**

**Location:** Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)

**Authors:** Ruifeng Sun, Jaewoong Lee, Dewan Artadji, Mark E Robinson, Kohei Kume, Zhangliang Cheng, Kadriye Nehir Cosgun, Lai N Chan, Etienne Leveille, Markus Muschen

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 322. Hemophilia A and B: Clinical and Epidemiological: Poster II**

[2584: Characterizing an Underdiagnosed Condition: Hemophilia in Females](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Valentina Restrepo, Stephanie Prozora, Evangelia Louizos, Layla N Van Doren, Robert D Bona

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 509. Bone Marrow Failure and Cancer Predisposition Syndromes:**

**Congenital: Poster II**

[2705: PLK1 Acts in Homologous Recombinatorial Repair and in Mitosis As Synthetically Lethal with the Fanconi Anemia/BRCA Pathway](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Barbara Burtness

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 602. Myeloid Oncogenesis: Basic: Poster II**

[2732: A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Prajwal Boddu, Rahul Roy, Manoj Pillai

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II**

[2880: Ziftomenib Combined with Intensive Induction \(7+3\) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Amer Zeidan

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 622. Lymphomas: Translational “ Non-Genetic: Poster II**

[3003: Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Ruifeng Sun, Jaewoong Lee, Mark E Robinson, Kohei Kume, Chuanzong Zhan, Zhangliang Cheng, Kadriye Nehir Cosgun, Lai N Chan, Etienne Leveille, Shalin Kothari, Samuel G. Katz, Markus Muschen

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II**

[3219: Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS \(icMDS\) Validate Database](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Wei Wei, Rory M. Shallis

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II**

[3216: Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Amer Zeidan

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II**

[3378: Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial \[SWOG S1702\]](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Terri Parker

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II**

[3628: Buprenorphine & Sickle Cell: How Pediatric and Adult Providers Differ in Prescribing Habits and Evolving Pain Management Styles](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jennifer A. Afranie-Sakyi, Max Jordan Nguemeni Tiako, Kimberly S. Vasquez, Layla N Van Doren, Cecelia Calhoun

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II**

[3644: Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Kunal C Potnis, Satoko Ito, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Amer M. Zeidan, Jan Philipp Bewersdorf, George Goshua

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II**

[3669: Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Satoko Ito, Justine Ryu, Kunal C Potnis, Aram Bidikian, George Goshua

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 904. Outcomes Research: Hemoglobinopathies: Poster II**

[3681: Large Scale Community-Based Sickle Cell Surveillance in an Aboriginal Population from Western India](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Lakshmanan Krishnamurti



**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II**

[3775: Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell \(CART\) and Bispecific T-Cell Engager \(BiTE\) Therapies in Relapsed/Refractory Multiple Myeloma \(RRMM\) at the Yale Cancer Center Network \(YCCN\)](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Poy Theprungsirikul, Rong Wang, Man-Yee Merl, Shi-Yi Wang, MD, Natalia Neparidze, MD

**Sunday, December 8; 6:00 PM-8:00 PM**

**Session: 908. Outcomes Research: Myeloid Malignancies: Poster II**

[3795: Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Amer M. Zeidan, Scott Huntington

**Monday, December 9; 10:30 AM-12:00 PM**

[905: Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases](#)

**Location:** Room 6B (San Diego Convention Center)

**Moderator:** George Goshua

**Monday, December 9; 10:45 AM**

**Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials**

[782: Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma](#)

**Location:** San Diego Ballroom AB (Marriott Marquis San Diego Marina)

**Author:** Scott Huntington

**Monday, December 9; 10:45 AM**

**Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes**

[788: Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia](#)

**Location:** Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

**Authors:** Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf

**Monday, December 9; 11:15AM**

**Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML**

[736: Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial \(BLAST AML-2\)](#)

**Location:** Grand Hall B (Manchester Grand Hyatt San Diego)

**Authors:** Jessica M. Stempel, Amer M. Zeidan, Rory M. Shallis, Nikolai A. Podoltsev, Lourdes M Mendez, Jan Philipp Bewersdorf, Tariq Kewan

**Monday, December 9; 2:45 PM-4:15 PM**

[605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma](#)

**Location:** Ballroom 20CD (San Diego Convention Center)

**Moderator:** Coraline Mlynarczyk

**Monday, December 9; 2:45 PM-4:15 PM**

[114: Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III](#)

**Location:** Room 33 (San Diego Convention Center)

**Moderator:** Susanna Curtis

**Monday, December 9; 3:30PM**

**Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment**

[625: Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?](#)

**Location:** Grand Hall B (Manchester Grand Hyatt San Diego)

**Author:** Tariq Kewan

**Monday, December 9; 4:30 – 6:30PM**

[625: T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?](#)

**Location:** Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

**Moderator:** Tarsheen Sethi

**Monday, December 9; 4:30 PM**

[904: Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease](#)

**Location:** Room 6DE (San Diego Convention Center)

**Moderator:** Cece Calhoun

**Monday, December 9; 4:30 PM-6:00 PM**

[605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma](#)

**Location:** Ballroom 20CD (San Diego Convention Center)

**Moderator:** Markus Muschen

**Monday, December 9; 4:30 PM**

**Session: 904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease**

[1063: Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease](#)

**Location:** Room 6DE (San Diego Convention Center)

**Authors:** Priyanshi Maurya, Jingchen Liang, Daniel Prior, Sai Prasad Ramachandran, Yanhong Deng, Lakshmanan Krishnamurti

**Monday, December 9; 5:15 PM**

**622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies**

[976: Metabolic Determinants of Ferroptosis in B-Cell Lymphoma](#)

**Location:** Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)

**Authors:** Etienne Leveille, Eden Bramson, Mark E Robinson, Thierry Bertomeu, Andrew Chatr-Aryamontri, Shalin Kothari, Markus Muschen

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 102. Iron Homeostasis and Biology: Poster III**

[3851: Mouse Models of Hereditary Xerocytosis-Associated PIEZO1 Mutations Reveal Genotype-Phenotype Differences in Hematological Defects and Iron Loading](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Karin E Finberg, Ludmila Peres Diaz

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III**

[3899: Sickle Pain-Related Impact \(SPiRIt\): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Nitya Bakshi

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 602. Myeloid Oncogenesis: Basic: Poster III**

[4117: Unraveling the Drivers of the Stress Granule Signature in Splicing Factor-Mutant Myeloid Malignancies](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Giulia Biancon and Stephanie Halene

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 602. Myeloid Oncogenesis: Basic: Poster III**

[4118: Ppara Deletion Promotes Monocytic Leukemia Granulocytic Differentiation](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Anish Sharda, Lourdes M Mendez

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 603. Lymphoid Oncogenesis: Basic: Poster III**

[4125: Identification of High-Efficiency  \$\beta\$ -Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Zhangliang Cheng, Salim Oulghazi, Philipp Berning, David Fonseca-Arce, Kohei Kume, Jake Fontaine, Lai N Chan, Jaewoong Lee, Markus Muschen

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III**

[4164: Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Mark E Robinson, Qin Li, Chang Zhang, Chuanzong Zhan, Zhangliang Cheng, Kohei Kume, Kadriye Nehir Cosgun, Shalin Kothari, Nikol Agadzhanian, Daisuke Nakada, Markus Muschen

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I**

[1412: Targeting  \$\beta\$ -Catenin Protein Degradation in Refractory B-Cell Malignancies](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Philipp Berning, David Fonseca-Arce, Etienne Leveille, Shalin Kothari, Markus Muschen

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III**

[4211: Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients \(pts\) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia \(ALL\) in the ECOG-ACRIN E1910 Randomized Phase III Trial](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Nikolai A. Podoltsev

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III**

[4253: Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III**

[4436: Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Ahmad Kiwan, Tariq Kewan, Alexa Siddon, Stephanie Halene, Tarsheen Sethi, Francine M. Foss

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III**

[4440: Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/S \$\alpha\$ zary Syndrome Patients with Worse Survival Outcomes](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Ahmad Kiwan, Tariq Kewan, Mina Xu, Alexa Siddon, Michael Girardi, Tarsheen Sethi, Francine M. Foss

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III**

[4585: Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jan Philipp Bewersdorf, Rory M. Shallis, Lourdes Mendez, Nikolai A. Podoltsev, Tariq Kewan, Stephanie Halene, Amer M. Zeidan

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III**

[4582: ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Tariq Kewan, Luisa Ladel, Ahmad Kiwan, Lourdes M Mendez

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III**

[4590: Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents](#)

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Amer Zeidan

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III**

[5007: Prediction of Event Free Survival in Hematopoietic Cell Transplantation: A Machine Learning Clustering and Proximity Analysis](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Rajagopalan Subramaniam, Michael Kane, Lakshmanan Krishnamurti

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III**

[5009: Implementation of American Society of Hematology \(ASH\) Neuro-Related Guidelines at a Sickle Cell Center: How Are We Doing?](#)

**Location:** Halls G-H (San Diego Convention Center)

**Authors:** Jennifer A. Afranie-Sakyi, Modupe Karimi, Janis Bozzo, Joanna Cole, Layla N Van Doren, Cecelia Calhoun

**Monday, December 9; 6:00 PM-8:00 PM**

**Session: 908. Outcomes Research: Myeloid Malignancies: Poster III**

*5189: Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents*

**Location:** Halls G-H (San Diego Convention Center)

**Author:** Amer Zeidan